SHURUI Single-Port Surgical Robot

The SHURUI Single-Port Surgical Robot (model SR-ENS-600) represents China’s first NMPA-approved single-port laparoscopic surgical system. Developed by Surgerii, the system employs proprietary snake-arm instruments made from superelastic nickel-titanium alloy, enabling multi-degree-of-freedom operations through a single 2.5cm incision.

Product Overview

SHURUI addresses the fundamental limitation of conventional single-port surgery: the “chopstick effect” where instruments entering through the same port compete for space and limit triangulation. Rather than using rigid articulated instruments, Surgerii’s approach uses continuum mechanism technology that allows instruments to bend and curve within the body cavity, achieving surgical triangulation without the constraints of traditional designs.

The system achieved several regulatory firsts: the first single-port surgical robot to enter China’s innovative medical device fast-track pathway (2020), the first such system to receive NMPA approval (2023), and in 2025, the only CE-certified single-port surgical robot approved for pediatric use. This positions SHURUI as both a domestic alternative to imported systems and a potential competitor in international markets.

Key Features

Snake-Arm Instrument Technology: The surgical instruments employ a “deformable dural continuum mechanism” constructed from nickel-titanium alloy. This design provides high payload capacity and reliability while maintaining flexibility that rigid-arm robots cannot match. The instruments feature redundant structural backbones, ensuring continued operation even if a single backbone fractures.

Single-Incision Access: A 2.5cm diameter multi-channel trocar delivers one 3D endoscope and three surgical instruments to the operative site. This approach minimizes external scarring—particularly relevant for cosmetically sensitive patients—while maintaining the precision of robotic assistance.

Eight-Direction Articulating Endoscope: The 3D high-definition electronic endoscope uses an eight-direction dual-segment internal articulation design, providing wide field-of-view adjustment with clear imaging and accurate color reproduction.

Motion Scaling: Surgeons can set different scaling ratios for teleoperated motion, enhancing precision during delicate dissection and reducing unintended tissue damage.

Dual Safety Architecture: The system incorporates two independent hardware systems for safety monitoring, with continuous motion monitoring throughout procedures and multiple emergency process control plans.

Technical Specifications

At 2.5cm trocar diameter with three nickel-titanium snake-arm instruments, SHURUI’s SR-ENS-600 reaches multi-specialty targets through a single incision that rigid multi-port systems require three to five ports to access.

Clinical Applications

SHURUI has demonstrated clinical utility across multiple surgical specialties:

Urology: Radical prostatectomy, partial nephrectomy, adrenalectomy, cystectomy. The system completed Asia’s first pure single-port radical prostatectomy and partial nephrectomy for kidney cancer.

Gynecology: Hysterectomy, myomectomy, ovarian surgery. NMPA approval covers gynecologic laparoscopic procedures with demonstrated efficacy in complex cases.

General Surgery: Cholecystectomy, gastrectomy, colorectal procedures. The 2025 NMPA expansion added general surgery to approved indications.

Thoracic Surgery: Pulmonary wedge resection, lobectomy. The system received NMPA approval for thoracic procedures in May 2025.

Pediatric Surgery: CE certification extends to pediatric patients, and Surgerii has performed procedures on patients as young as 7 days old, demonstrating the system’s adaptability to smaller anatomical scales.

Regulatory Status

The CE certification under MDR EU2017/745 makes SHURUI the second single-port surgical robot approved for European markets, following Intuitive Surgical’s da Vinci SP (which received CE Mark in 2024). Notably, SHURUI is the only single-port system with CE approval for pediatric use.

Clinical Evidence

As of late 2025, Surgerii reports over 3,000 robot-assisted procedures performed domestically across more than 70 Grade A tertiary hospitals. The company has developed over 80 surgical techniques through clinical collaboration, including several “first” procedures:

• Asia’s first pure single-port radical prostatectomy
• Asia’s first pure single-port partial nephrectomy for kidney cancer
• World’s first retroperitoneal adrenal tumor resection via single-port approach

The company has also participated in nearly 50 procedures internationally as part of its global expansion strategy, with European clinical collaboration through IRCAD.

Frequently Asked Questions

What makes SHURUI different from da Vinci SP?

Both systems enable single-port surgery, but they use fundamentally different instrument technologies. Da Vinci SP employs cable-driven articulated instruments similar to its multi-port systems, while SHURUI uses continuum mechanism “snake-arm” instruments made from nickel-titanium alloy. Surgerii claims advantages in flexibility and pediatric applications. Additionally, SHURUI has CE certification for pediatric patients, while da Vinci SP is approved only for adults in Europe.

How does single-port surgery benefit patients?

Single-port surgery reduces the number and total length of incisions compared to multi-port laparoscopic approaches. Potential benefits include reduced surgical trauma, decreased postoperative pain, faster recovery times, and improved cosmetic outcomes with a single hidden incision (often placed in the umbilicus).

What training is required to operate SHURUI?

The system is intended for use by trained surgeons in an operating room environment. Surgerii has established clinical partnerships with over 70 hospitals in China and created the European Clinical Excellence Center with IRCAD for international training. Specific training requirements follow standard surgical robot credentialing processes.

Is SHURUI available outside China?

With CE certification obtained in August 2025, SHURUI is now approved for commercial distribution in European Union member states. The company has indicated strategic focus on the European market. FDA approval has not been obtained, so the system is not available in the United States.